Edition:
United Kingdom

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

5.73USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.73
Open
--
Day's High
--
Day's Low
--
Volume
1,400
Avg. Vol
99,945
52-wk High
$8.62
52-wk Low
$4.98

Select another date:

Fri, Dec 15 2017

BRIEF-Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria

* ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY

BRIEF-Aratana Therapeutics Announces Proposed Public Offering

* ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

BRIEF-ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE

* ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE

BRIEF-Aratana Therapeutics reports Q3 loss per share of $0.21

* Aratana Therapeutics reports third quarter 2017 financial results

BRIEF-Aratana Therapeutics announces launch of Entyce

* Aratana Therapeutics announces launch of Entyce® (capromorelin oral solution)

BRIEF-Aratana Therapeutics files for mixed shelf offering of up to $100 mln

* Aratana therapeutics inc files for mixed shelf offering of up to $100 million - sec filing‍​ Source text for Eikon: (http://bit.ly/2vzfNhB) Further company coverage:

BRIEF-Aratana Therapeutics reports Q2 loss per share $0.26

* Aratana Therapeutics reports second quarter 2017 financial results

BRIEF-Aratana Therapeutics announces positive results for at-003

* Aratana Therapeutics Inc - ‍results from study met protocol-defined efficacy success criteria, which were statistically significant for at-003​

Select another date: